Apellis Pharmaceuticals, a global biopharmaceutical company, announced FDA approval of Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on Feb. 17, 2023. The first and only FDA-approved treatment for GA, according to a company press release, approval of pegcetacoplan injection was based on positive Phase III clinical trial results from two studies (OAKS and DERBY) that found it reduced the rate of GA lesion growth compared to sham.
